James Foran, MD
Hematology & Oncology · Jacksonville, FLNPI 1992749139
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $116,143 of the $164,256 with a category attached, or 70.7%. 24 manufacturers reported payments, led by Novartis at 30.8% of the total. Reporting peaked in 2020 at $49,798 and has fallen 55.2% since, to $22,291 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $1216.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$51K
- Syndax Pharmaceuticals, Inc.$12K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Servier Pharmaceuticals LLC$9K
- Astellas Pharma Global Development$8K
- Bristol Myers Squibb$7K
- plus $68K from 18 others
Across 286 payments — averaging $15,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2M
- AbbVie$449K
- Bristol Myers Squibb$421K
- Novartis$411K
- Stemline Therapeutics Inc.$258K
- Boehringer Ingelheim$147K
- plus $693K from 11 others
What the payments were for
- Consulting fees$116,14371%
- Speaking & faculty fees$22,26114%
- Travel & lodging$23,30014%
- Food & beverage$2,5512%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $50,670 |
| Syndax Pharmaceuticals, Inc. | 15 | $11,640 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $10,063 |
| Servier Pharmaceuticals LLC | 15 | $8,608 |
| Astellas Pharma Global Development | 8 | $7,921 |
| Bristol Myers Squibb | 6 | $7,179 |
| Amgen | 2 | $7,124 |
| Taiho Oncology, Inc. | 3 | $5,938 |
| Stemline Therapeutics Inc. | 3 | $5,802 |
| Pfizer | 6 | $5,450 |
| Daiichi Sankyo Inc. | 3 | $5,250 |
| Beigene USA, Inc. | 7 | $4,637 |
| CTI Biopharma Corp. | 3 | $4,536 |
| Jazz Pharmaceuticals Inc. | 11 | $4,383 |
| Agios Pharmaceuticals, Inc. | 10 | $4,305 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,102 |
| Rigel Pharmaceuticals, Inc. | 7 | $3,657 |
| Sanofi | 1 | $3,125 |
| Geron Corporation | 3 | $3,047 |
| AstraZeneca | 2 | $2,241 |
| Genentech USA, Inc. | 1 | $1,925 |
| Boehringer Ingelheim International GmbH | 1 | $1,692 |
| Acceleron Pharma, Inc. | 1 | $845 |
| Gilead | 1 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,256 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 31 | $466,657 |
| RezurockBelumosudil Mesylate | 19 | $377,591 |
| JakafiRuxolitinib Phosphate | 15 | $259,359 |
| ScemblixAsciminib Hydrochloride | 11 | $237,539 |
| SprycelDasatinib | 20 | $168,897 |
| InqoviDecitabine/Cedazuridine | 20 | $166,172 |
| VenclextaVenetoclax | 11 | $36,707 |
| Deferasirox | 12 | $9,393 |
| ValacyclovirValacyclovir Hcl | 37 | $1,622 |
| Tacrolimus | 25 | $1,349 |
| Cefdinir | 22 | $1,116 |
| Dapsone | 16 | $874 |
| Acyclovir | 91 | $855 |
| Fluconazole | 19 | $684 |
| Hydroxyurea | 31 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $4,637 | $466,65731 claims |
| NovartisScemblix | $50,670 | $237,53911 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $4,102 | $168,89720 claims |
| Taiho Oncology, Inc.Inqovi | $5,938 | $166,17220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.